MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing

Outpatient molecular syndromic panels for infectious disease identification are covered when multiple specific general criteria are met: a clinical indication requiring multi‑pathogen evaluation, use within intended validated populations and sample types, and evidence that results will alter management. Expanded panels (≥6 targets) have additional specialist, severity, or setting requirements by panel type (respiratory, GI, UG/AG, ME, BSI, UTI), duplicate or repeat testing is limited (generally not within 14 days), and regulatory/registration (MolDX/TA), CLIA/FDA compliance, and specific documentation (clinical indication, provider specialty, sample collection, parallel testing) are required.

"Outpatient molecular syndromic panel testing is covered when all general coverage criteria below are met (see separate entries)."

Sign up to see full coverage criteria, indications, and limitations.